Guidance on minimising disruptions to the conduct and integrity of clinical trials of medicines during COVID-19

This has been developed to assist those involved in running clinical trials of medicines. It aims to help avoid disruptions as result of continuing pandemic and to support appropriate incorporation of available flexibilities into normal practice for benefit of trial participants.

Medicines and Healthcare products Regulatory Agency